Immunome, Inc.IMNMNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank41
3Y CAGR-20.9%
5Y CAGR-48.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-20.9%/yr
vs -50.4%/yr prior
5Y CAGR
-48.2%/yr
Recent acceleration
Acceleration
+29.5pp
Accelerating
Percentile
P41
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.38% |
| Q3 2025 | 8.99% |
| Q2 2025 | -6.06% |
| Q1 2025 | 2.34% |
| Q4 2024 | 9.66% |
| Q3 2024 | 36.51% |
| Q2 2024 | 16.20% |
| Q1 2024 | -25.31% |
| Q4 2023 | 83.77% |
| Q3 2023 | 1.27% |
| Q2 2023 | 47.84% |
| Q1 2023 | -17.34% |
| Q4 2022 | 6.83% |
| Q3 2022 | 3.12% |
| Q2 2022 | -10.26% |
| Q1 2022 | 3.38% |
| Q4 2021 | 7.76% |
| Q3 2021 | 28.04% |
| Q2 2021 | 30.71% |
| Q1 2021 | -14.30% |
| Q4 2020 | 90.63% |
| Q3 2020 | 42.65% |
| Q2 2020 | 52.41% |
| Q1 2020 | 18.42% |
| Q4 2019 | -6.17% |
| Q3 2019 | 66.72% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |